Trial reportNature communications2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Transformers meets neoantigen detection: a systematic literature review.Journal of integrative bioinformatics · 2024Pooled it
- A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.BMC cancer · 2025Trial
- CTGF: The remodeler of the tumor immune microenvironment (Review).Oncology reports · 2026Review
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy.Nature reviews. Cancer · 2026Review
- From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.Journal of personalized medicine · 2026Review
- A Framework for Comparing Mouse Neoantigen Immunogenicity.bioRxiv : the preprint server for biology · 2026Article
- AblatingFrontiers in immunology · 2026Article
- Dynamic peripheral immune monitoring during checkpoint blockade: a framework for interpreting response, toxicity and resistance.Frontiers in immunology · 2026Review
- Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity.Frontiers in immunology · 2026Article
- Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade.Frontiers in immunology · 2026Review
- The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Journal of hematology & oncology · 2025Review
- Properties of CD8 T-cell-recognized neoantigens in different tumor types.Immuno-oncology technology · 2025Article
- Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities.Journal of experimental & clinical cancer research : CR · 2025Review
- A roadmap for T cell receptor-peptide-bound major histocompatibility complex binding prediction by machine learning: glimpse and foresight.Briefings in bioinformatics · 2025Review
- FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer.Cell death & disease · 2025Article
- Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.Discover oncology · 2025Review
- A DNA alteration and methylation co-detection method for clinical purpose.EMBO molecular medicine · 2025Article
- Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.Immunotherapy · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 3 countries.
Jeppe Sejerø Holm *Experimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Samuel A Funt *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-7235-6319
Annie BorchExperimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Kamilla Kjærgaard MunkExperimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Anne-Mette BjerregaardExperimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.ORCID http://orcid.org/0000-0002-1831-6746
James L ReadingCancer Immunology Unit, Research Department of Hematology and Cancer Research UK, Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-5381-978X
Colleen MaherDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0003-1117-9272
Ashley RegazziDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-6019-1852
Phillip WongDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-6360-849X
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2938-6627
Gopa IyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-5093-6099
Tripti TamhaneExperimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.ORCID http://orcid.org/0000-0001-6417-3304
Amalie Kai BentzenExperimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Nana Overgaard HerschendExperimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Susan De WolfDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Alexandra SnyderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Taha MerghoubDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0002-1518-5111
Jedd D WolchokDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0001-6718-2222
Morten NielsenSection of Bioinformatics, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.ORCID http://orcid.org/0000-0001-7885-4311
Jonathan E RosenbergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Dean F Bajorin *Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.ORCID http://orcid.org/0000-0003-4001-7088
Sine Reker Hadrup *Experimental and Translational Immunology, Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark. sirha@dtu.dk.
Memorial Sloan Kettering Cancer Center · USTechnical University of Denmark · DKCancer Research UK · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BAJORIN, DEAN F. · 2018 to 2024
$11.8MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MNCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745
Abstract
CD8
Indexed as
Carcinoma, Transitional CellUrinary Bladder NeoplasmsB7-H1 AntigenCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsB7-H1 AntigenImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.